80 results
8-K
SLNO
Soleno Therapeutics Inc
16 Aug 23
Departure of Directors or Certain Officers
9:00am
, and company management teams on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization from
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
. The designation reflects the Agency’s determination that, based on an assessment of the preliminary data from the Phase 3 clinical development program
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
8 Jun 20
Regulation FD Disclosure
5:04pm
n = 60
Changes in HQ-CT after 13 or 26 Weeks of DCCR Treatment in C601 and C602 | © 2020 Soleno Therapeutics
PWS Outcomes Assessment – Interim
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
proceeds from the warrant financing under the Securities Purchase Agreement, management’s assessment of the top-line data results from the randomized
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
18 Dec 14
Capnia Reports Third Quarter 2014 Financial Results
12:00am
assessment of ETCO in the newborn setting, our initial target market, and the American Academy of Pediatrics recommends its use in newborns with jaundice
8-K
EX-99.1
a0s4btc etuwiii
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K/A
EX-99.1
0bk7b hxrq0
10 Apr 17
Other Events
12:00am
S-1/A
zspxfwa
1 Jul 14
IPO registration (amended)
12:00am
S-1/A
EX-10.19
gz2u6ld5gd7r5 onyxm
1 Jul 14
IPO registration (amended)
12:00am